Using NF-κB as a molecular target for theranostics in radiation oncology research

Yu Chang Liu, I. Tsang Chiang, Fei Ting Hsu, Jeng Jong Hwang

Research output: Contribution to journalReview articlepeer-review

29 Citations (Scopus)


Resistance of cancer cells to chemotherapy and/or radiotherapy is a major challenge to current anticancer treatment. The NF-κB signaling pathway plays an important role in tumor development and progression, and results in unsatisfactory treatment outcome. Inhibition of the NF-κB signaling cascade may sensitize the resistant cancer cells to chemotherapy and/or radiotherapy. Here, the correlation of NF-κB molecules with carcinogenesis and tumor progression, along with its significance in clinical practice, is reviewed. The potential clinical application of NF-κB and its associated molecules as diagnostic and therapeutic targets is also discussed.

Original languageEnglish
Pages (from-to)139-146
Number of pages8
JournalExpert Review of Molecular Diagnostics
Issue number2
Publication statusPublished - Mar 2012
Externally publishedYes


  • chemoresistance
  • IKK inhibitor
  • molecular targeting
  • nanoparticle
  • NF-kB
  • radioresistance
  • sorafenib

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine


Dive into the research topics of 'Using NF-κB as a molecular target for theranostics in radiation oncology research'. Together they form a unique fingerprint.

Cite this